Sagimet Biosciences Inc. Series A Common Stock (SGMT) is a publicly traded Healthcare sector company. As of October 29, 2026, SGMT trades at $10.80 with a market cap of $738.87M and a P/E ratio of -5.63. SGMT moved +0.00% today. Year to date, SGMT is +79.30%; over the trailing twelve months it is +30.34%. Its 52-week range spans $1.73 to $11.45. Analyst consensus is strong buy with an average price target of $28.46. Rallies surfaces SGMT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Sagimet says partner trial shows denifanstat sustains acne efficacy through 52 weeks: Sagimet said an Ascletis Phase 3 open-label extension in China showed sustained acne improvement with denifanstat through 52 weeks, with tolerability broadly consistent with earlier findings. The results will be presented at the 2026 Fall Clinical Dermatology Conference, and Sagimet said its U.S. AURORA Phase 3 trial has activated sites and begun screening patients.
| Metric | Value |
|---|---|
| Price | $10.80 |
| Market Cap | $738.87M |
| P/E Ratio | -5.63 |
| EPS | $-1.58 |
| Dividend Yield | 0.00% |
| 52-Week High | $11.45 |
| 52-Week Low | $1.73 |
| Volume | 30.31K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-51.04M |
| Gross Margin | 0.00% |
12 analysts cover SGMT: 0 strong buy, 11 buy, 0 hold, 1 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $28.46.